Heyuan Biotech announced that Aofumin® recombinant human albumin injection, a Class 1 innovative drug independently developed by the company, was successfully included in the 2026 edition of the National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue. The medical insurance classification is Class B, an exclusive variety, and the indication is the treatment of liver cirrhosis hypoalbuminemia. The agreement is valid from January 1, 2027 to December 31, 2028, and the new medical insurance catalogue will be officially implemented on January 1, 2027. This product is the world's first recombinant protein drug based on the rice endosperm cell expression system. It was approved for marketing in July 2025. This inclusion in medical insurance is beneficial to product marketing and sales, and there is uncertainty about the specific sales situation.

Zhitongcaijing · 2d ago
Heyuan Biotech announced that Aofumin® recombinant human albumin injection, a Class 1 innovative drug independently developed by the company, was successfully included in the 2026 edition of the National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue. The medical insurance classification is Class B, an exclusive variety, and the indication is the treatment of liver cirrhosis hypoalbuminemia. The agreement is valid from January 1, 2027 to December 31, 2028, and the new medical insurance catalogue will be officially implemented on January 1, 2027. This product is the world's first recombinant protein drug based on the rice endosperm cell expression system. It was approved for marketing in July 2025. This inclusion in medical insurance is beneficial to product marketing and sales, and there is uncertainty about the specific sales situation.